The efficacy of this approach is currently unclear across tumor types, as some mutations are only known to be prognostic for response in particular situations; some early attempts at matching therapies failed for this reason, e.g. the use of BRAF inhibitors in BRAF mutant colorectal cancer [15]. Here, BRAF is linked to colorectal cancer.